Roche plans to fast-track its anti-obesity drugs to challenge rivals Eli Lilly and Novo Nordisk in the booming market after unveiling promising data for a weight-loss pill.
Thomas Schinecker, chief executive of the Swiss pharmaceutical company, told the Financial Times that Roche’s first obesity drugs would come to market “significantly faster than people are expecting”, potentially by 2028.
The treatments, acquired in an up to $3.1bn takeover of biotech Carmot last year, includes a weight-loss jab set to enter phase II trials and a pill that has given users 6.1 per cent reduction in weight compared with a placebo after four weeks.
您已閱讀17%（640字），剩餘83%（3104字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。